Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
Active, not recruiting · NCT04848337 · Registry updated 2026-05-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, metastatic prostate carcinoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-05-11 | NCT04848337 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hoosier Cancer Research Network | 7 |
| Merck Sharp & Dohme LLC | 650 |
| University of Michigan Rogel Cancer Center | 63 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| Froedtert and The Medical College of Wisconsin | Milwaukee | United States | 21 |
| Oregon Health | Portland | United States | 3 |
| University of Michigan Health System | Ann Arbor | United States | 38 |
| Winship Cancer Instituted of Emory University | Atlanta | United States | 1 |